Homepage Top Section2

The funds will be channelled towards advancing multiple proprietary pipeline programmes into clinical trials, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. This significant

This development creates new pathways for the vaccine’s procurement, distribution, and reimbursement by both public and private payers. In response to the global mpox outbreak, since 2022, JYNNEOS

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live

Utidelone’s unique properties allow it to cross the blood-brain barrier (BBB), a capability supported by both preclinical and clinical studies. A Phase II study involving utidelone in combination

Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after

This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and

With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement.

This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical

This development marks the first nonsteroidal medication authorised to treat DMD patients with all genetic variants of a rare neurological disorder. A histone deacetylase (HDAC) inhibitor, Duvyzat can